A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.

The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Platelets are cells that help your blood clot, and it was so unusual to see blood clots combined with low platelet levels, ...

Zachary Levi, known for his role as the titular character in Shazam! Fury of the Gods, is facing financial difficulties after ...

Michela Tindera But despite losing Read and D’Amelio’s support, Starboard is still pushing ahead with its campaign. Yesterday, October 22nd, at an activist investor conference in New York, Starboard ...

Activist investors tend to rely on an element of surprise to catch their target company off guard: quietly building up a stake and swooping in with a slide deck full of strategic changes at just the ...

Social media users are spreading new levels of misinformation based on discredited claims that nanobots are lurking in ...

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...

Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...